- Home
- LCTX vs TLSI Comparison
LCTX vs TLSI Comparison
Compare LCTX & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LCTX
- TLSI
- Stock Information
- Founded
- LCTX 1990
- TLSI 2010
- Country
- LCTX United States
- TLSI United States
- Employees
- LCTX N/A
- TLSI N/A
- Industry
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- TLSI Medical Specialities
- Sector
- LCTX Health Care
- TLSI Health Care
- Exchange
- LCTX Nasdaq
- TLSI Nasdaq
- Market Cap
- LCTX 165.6M
- TLSI 166.8M
- IPO Year
- LCTX N/A
- TLSI N/A
- Fundamental
- Price
- LCTX $0.88
- TLSI $5.14
- Analyst Decision
- LCTX Strong Buy
- TLSI Strong Buy
- Analyst Count
- LCTX 3
- TLSI 2
- Target Price
- LCTX $5.67
- TLSI $14.00
- AVG Volume (30 Days)
- LCTX 327.9K
- TLSI 69.8K
- Earning Date
- LCTX 11-07-2024
- TLSI 08-14-2024
- Dividend Yield
- LCTX N/A
- TLSI N/A
- EPS Growth
- LCTX N/A
- TLSI N/A
- EPS
- LCTX N/A
- TLSI N/A
- Revenue
- LCTX $6,186,000.00
- TLSI $24,736,000.00
- Revenue This Year
- LCTX N/A
- TLSI $61.24
- Revenue Next Year
- LCTX $119.00
- TLSI $47.32
- P/E Ratio
- LCTX N/A
- TLSI N/A
- Revenue Growth
- LCTX N/A
- TLSI 67.75
- 52 Week Low
- LCTX $0.77
- TLSI $3.32
- 52 Week High
- LCTX $1.61
- TLSI $10.42
- Technical
- Relative Strength Index (RSI)
- LCTX 47.97
- TLSI 43.52
- Support Level
- LCTX $0.83
- TLSI $4.80
- Resistance Level
- LCTX $0.94
- TLSI $5.47
- Average True Range (ATR)
- LCTX 0.06
- TLSI 0.31
- MACD
- LCTX 0.00
- TLSI -0.01
- Stochastic Oscillator
- LCTX 40.38
- TLSI 34.69
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.